Annika M. Hofstetter

Annika M. Hofstetter

Auto-generated profile, based on publicly available information

Annika M. Hofstetter

Department of Pediatrics, University of Washington, Seattle, Washington;

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2017 in Vaccine
Verified
Journal Article
Closed access
AHAnnika M. Hofstetter
Annika M. Hofstetter
JRJeffrey D. Robinson
Jeffrey D. Robinson
KLKatherine Lepere
Katherine Lepere
MCMorgan Cunningham
Morgan Cunningham
NENicole Etsekson
Nicole Etsekson
DODouglas J. Opel
Douglas J. Opel

1 October 2015 in Vaccine
Verified
Journal Article
Closed access
AHAnnika M. Hofstetter
Annika M. Hofstetter
NDNathalie DuRivage
Nathalie DuRivage
CVCelibell Y. Vargas
Celibell Y. Vargas
SCStewin Camargo
Stewin Camargo
DVDavid K. Vawdrey
David K. Vawdrey
MSMelissa S. Stockwell
Melissa S. Stockwell

1 May 2021 in Academic Pediatrics
Verified
Journal Article
Closed access
AHAnnika M. Hofstetter
Annika M. Hofstetter
SSStanley Schaffer
Stanley Schaffer

1 April 2014 in Pediatrics
Verified
Journal Article
Closed access
PDF file
AHAnnika M. Hofstetter
Annika M. Hofstetter
KJKathleen Jakob
Kathleen Jakob
NKNicola P. Klein
Nicola P. Klein
CDCornelia L. Dekker
Cornelia L. Dekker
KEKathryn M Edwards
Kathryn M Edwards
PLPhilip LaRussa
Philip LaRussa
OBJECTIVE: Live vaccines are generally contraindicated in patients with DiGeorge syndrome (DGS), a congenital disorder characterized by cellular immune deficiency. Vaccine utilization and safety in this population are not well described. This study examined vaccination patterns and adverse events following live immunization (AEFLI) in these individuals. METHODS: A multicenter retrospective cohort study was conducted in subjects with DGS confirmed by fluorescence in situ hybridization assay (chromosome 22q11.2 microdeletion). Live vaccine-preventable illnesses, vaccination coverage and timeliness, and AEFLIs in the 56-day window after live vaccination were examined. Bivariate and multivariable analyses assessed the impact of demographics medical history, timing of diagnostic confirmation, and preceding immune function on vaccination patterns and AEFLIs. RESULTS: Of 194 subjects, 77% and 75% received measles-mumps-rubella (MMR) and varicella vaccines, respectively; 58% completed recommended vaccinations by age 19 to 35 months. Adverse events occurred after 14% and 20% of MMR and varicella vaccine doses, respectively. Most events were minor, few were serious, and no deaths were reported in post–live vaccination windows. Although early diagnostic confirmation negatively affected live vaccination coverage and timeliness (P < .001), baseline CD4% did not differ between subjects who did or did not receive live vaccines by 12 to 18 months. Among varicella vaccine recipients, those with a subsequent adverse event had a lower preceding CD4% (24.8% ± 7.3%) than those without (35.5% ± 11.7%) (P < .05); no CD4% differences were observed with MMR vaccination. Fourteen unvaccinated subjects experienced live vaccine–preventable illnesses. CONCLUSIONS: Live vaccines were frequently given and generally well-tolerated among patients with DGS with mild-to-moderate immunosuppression.

1 September 2019 in Pediatrics
Verified
Journal Article
Closed access
AHAnnika M. Hofstetter
Annika M. Hofstetter
EJElizabeth N. Jacobson
Elizabeth N. Jacobson
MDM. Patricia Dehart
M. Patricia Dehart
JEJanet A. Englund
Janet A. Englund
BACKGROUND: Preterm infants are at increased risk for vaccine-preventable infections and associated complications. Limited studies describe timely vaccination of these vulnerable infants. METHODS: This retrospective cohort study included Washington State infants with birth hospitalizations at an urban academic medical center between 2008 and 2013. Demographic, clinical, and visit data from electronic health records were linked to vaccine data from the Washington State Immunization Information System. Completion of the recommended 7-vaccine series by 19 months of age was compared between preterm infants (born at <37 weeks’ gestation) and term/postterm infants (born at 37–43 weeks’ gestation) by using Pearson’s χ2 test and multivariable logistic regression. Secondary outcomes included 7-vaccine series completion by 36 months of age and receipt of individual vaccines in the series. Rotavirus, hepatitis A, and influenza vaccination was also assessed. RESULTS: Of study infants (n = 10 367), 19.3% were born prematurely. Preterm infants had lower 7-vaccine series completion compared with term/postterm infants by 19 months (47.5% vs 54.0%; adjusted odds ratio 0.77 [95% confidence interval 0.65–0.90]) and 36 months (63.6% vs 71.3%; adjusted odds ratio 0.73 [95% confidence interval 0.61–0.87]). Early preterm (23–33 weeks’ gestation) and late preterm (34–36 weeks’ gestation) infants had a lower rate of 7-vaccine series completion compared with term/postterm infants. Full influenza vaccination coverage by 19 months also differed between groups (early preterm: 47.7%; late preterm: 41.5%; term/postterm: 44.7%; P = .02). CONCLUSIONS: Over half of preterm infants were undervaccinated at 19 months; one-third failed to catch up by 36 months. Strategies to improve vaccination of these high-risk infants are needed.

1 February 2017 in Journal of Pediatric and Adolescent Gynecology
Verified
Journal Article
Closed access
AHAnnika M. Hofstetter
Annika M. Hofstetter
LLLauren Lappetito
Lauren Lappetito
MSMelissa S. Stockwell
Melissa S. Stockwell
SRSusan L. Rosenthal
Susan L. Rosenthal